PLoS ONE 2014-01-01

Monoclonal antibody targeting of fibroblast growth factor receptor 1c ameliorates obesity and glucose intolerance via central mechanisms.

Christopher J Lelliott, Andrea Ahnmark, Therese Admyre, Ingela Ahlstedt, Lorraine Irving, Feenagh Keyes, Laurel Patterson, Michael B Mumphrey, Mikael Bjursell, Tracy Gorman, Mohammad Bohlooly-Y, Andrew Buchanan, Paula Harrison, Tristan Vaughan, Hans-Rudolf Berthoud, Daniel Lindén

Index: PLoS ONE 9(11) , e112109, (2014)

Full Text: HTML

Abstract

We have generated a novel monoclonal antibody targeting human FGFR1c (R1c mAb) that caused profound body weight and body fat loss in diet-induced obese mice due to decreased food intake (with energy expenditure unaltered), in turn improving glucose control. R1c mAb also caused weight loss in leptin-deficient ob/ob mice, leptin receptor-mutant db/db mice, and in mice lacking either the melanocortin 4 receptor or the melanin-concentrating hormone receptor 1. In addition, R1c mAb did not change hypothalamic mRNA expression levels of Agrp, Cart, Pomc, Npy, Crh, Mch, or Orexin, suggesting that R1c mAb could cause food intake inhibition and body weight loss via other mechanisms in the brain. Interestingly, peripherally administered R1c mAb accumulated in the median eminence, adjacent arcuate nucleus and in the circumventricular organs where it activated the early response gene c-Fos. As a plausible mechanism and coinciding with the initiation of food intake suppression, R1c mAb induced hypothalamic expression levels of the cytokines Monocyte chemoattractant protein 1 and 3 and ERK1/2 and p70 S6 kinase 1 activation.